Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office

Investigational medicinal products submitted over the course of 3 years and authorized at the Clinical Trials Office of the Italian Medicines Agency as part of a request for authorization of clinical trials were scrutinized to identify those encompassing nanomedicines. The quality assessment reports...

Descripción completa

Detalles Bibliográficos
Autores principales: Dri, Diego Alejandro, Gaucci, Elisa, Torrieri, Ilaria, Carafa, Maria, Marianecci, Carlotta, Gramaglia, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318126/
https://www.ncbi.nlm.nih.gov/pubmed/35890333
http://dx.doi.org/10.3390/pharmaceutics14071438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318126/
https://www.ncbi.nlm.nih.gov/pubmed/35890333
http://dx.doi.org/10.3390/pharmaceutics14071438

Ejemplares similares